Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Entrada Therapeutics, Inc. (TRDA) had Return on Equity of -14.66% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.88M |
|
$-39.72M |
|
-- |
|
$0.88M |
|
$43.18M |
|
$-42.30M |
|
$2.62M |
|
$-39.68M |
|
$-39.68M |
|
$-39.72M |
|
$-39.72M |
|
$-39.72M |
|
$-39.72M |
|
$-42.30M |
|
$-42.05M |
|
41.84M |
|
41.84M |
|
$-0.95 |
|
$-0.95 |
|
| Balance Sheet Financials | |
$266.87M |
|
$6.51M |
|
$68.65M |
|
$335.52M |
|
$19.20M |
|
-- |
|
$45.47M |
|
$64.66M |
|
$270.85M |
|
$270.85M |
|
$270.85M |
|
38.82M |
|
| Cash Flow Statement Financials | |
$-41.70M |
|
$26.99M |
|
$0.10M |
|
$94.34M |
|
$79.74M |
|
$-14.61M |
|
$4.74M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4834.63% |
|
-4834.63% |
|
-- |
|
-4534.74% |
|
-4539.09% |
|
$-41.74M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
1.11 |
|
80.95 |
|
|
Return on Equity |
-14.66% |
-14.66% |
|
-11.84% |
|
-14.66% |
|
$6.98 |
|
$-1.00 |
|
$-1.00 |
|